Gross Profit Trends Compared: Viatris Inc. vs Ligand Pharmaceuticals Incorporated

Viatris vs Ligand: A Decade of Gross Profit Trends

__timestampLigand Pharmaceuticals IncorporatedViatris Inc.
Wednesday, January 1, 2014554020003669400000
Thursday, January 1, 2015661070004382200000
Friday, January 1, 20161034020004998500000
Sunday, January 1, 20171357360004976200000
Monday, January 1, 20182451160004572000000
Tuesday, January 1, 20191089350004444200000
Wednesday, January 1, 20201560000003796700000
Friday, January 1, 20212149570005575500000
Saturday, January 1, 20221434180006497000000
Sunday, January 1, 2023962650006438600000
Loading chart...

Unlocking the unknown

Gross Profit Trends: Viatris Inc. vs Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Viatris Inc. and Ligand Pharmaceuticals Incorporated have showcased distinct trajectories in their gross profit margins. From 2014 to 2023, Viatris Inc. consistently outperformed Ligand Pharmaceuticals, with its gross profit peaking at approximately $6.5 billion in 2022, marking a 77% increase from 2014. In contrast, Ligand Pharmaceuticals saw a more volatile journey, with its highest gross profit reaching around $245 million in 2018, a significant 342% rise from 2014. However, by 2023, Ligand's profits had decreased by 61% from its peak. This comparison highlights Viatris's steady growth and Ligand's fluctuating performance, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025